Overview

Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
Phase:
Phase 1
Details
Lead Sponsor:
Abbott
Treatments:
Immune Sera